Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received ...

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch in 2025.

The Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's Alzheimer's treatment for ...

Eli Lilly LLY announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive ...

However, the drugmaker's prospects look so strong that not only should it soon join the $1 trillion club, but it could even ...